# A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas

> **NCT03277729** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Fred Hutchinson Cancer Center** · enrollment: 53 (actual)

## Conditions studied

- Recurrent B-Cell Non-Hodgkin Lymphoma
- Recurrent Chronic Lymphocytic Leukemia
- Recurrent Diffuse Large B-Cell Lymphoma
- Recurrent Follicular Lymphoma
- Recurrent Lymphoplasmacytic Lymphoma
- Recurrent Mantle Cell Lymphoma
- Recurrent Marginal Zone Lymphoma
- Refractory B-Cell Non-Hodgkin Lymphoma
- Refractory Diffuse Large B-Cell Lymphoma
- Refractory Follicular Lymphoma
- Refractory Lymphoplasmacytic Lymphoma
- Refractory Mantle Cell Lymphoma
- Refractory Transformed Non-Hodgkin Lymphoma
- Recurrent Transformed B-Cell Non-Hodgkin Lymphoma
- Recurrent Transformed Chronic Lymphocytic Leukemia
- Refractory Marginal Zone Lymphoma
- Refractory Transformed B-Cell Non-Hodgkin Lymphoma
- Refractory Transformed Chronic Lymphocytic Leukemia
- Recurrent Small Lymphocytic Lymphoma
- Refractory Chronic Lymphocytic Leukemia
- Refractory Small Lymphocytic Lymphoma
- Recurrent Central Nervous System Lymphoma
- Refractory Central Nervous System Lymphoma

## Interventions

- **BIOLOGICAL:** Chimeric Antigen Receptor T-Cell Therapy
- **DRUG:** Cyclophosphamide
- **OTHER:** Laboratory Biomarker Analysis
- **PROCEDURE:** Leukapheresis
- **DRUG:** Fludarabine Phosphate

## Key facts

- **NCT ID:** NCT03277729
- **Lead sponsor:** Fred Hutchinson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2017-12-05
- **Primary completion:** 2024-03-29
- **Final completion:** 2039-03
- **Target enrollment:** 53 (ACTUAL)
- **Last updated:** 2026-01-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03277729

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03277729, "A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03277729. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*